PRAX Live signals | Maximize Profits with Getagraph.com

BUY 93541 min ago

@ $42.09

Issued: 14 Feb 2024 @ 14:09

Return: 11.83%

Previous signal: Feb 14 - 10:24

Previous signal: Sell

Return: -4.89 %

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 14:09):

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance...

Stats
Today's Volume	180 502
Average Volume	190 367
Market Cap	804.33M
EPS	$0 ( 2024-03-05 )
Next earnings date	( $-2.01 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.52
ATR14	$0.176 (0.37%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-12	Mastrocola Lauren	Sell	48	Common Stock
2024-02-12	Nemiroff Alex	Sell	51	Common Stock
2024-02-12	Souza Marcio	Sell	271	Common Stock
2024-01-12	Kelly Timothy Edwin	Buy	30 000	Stock Option (Right to Buy)
2024-01-12	Souza Marcio	Buy	100 000	Stock Option (Right to Buy)

INSIDER POWER
98.12
Last 99 transactions
Buy: 3 195 196 \| Sell: 875 304

Volume Correlation

Long: 0.08 (neutral)

Short: -0.66 (moderate negative)

Signal:(52.405) Neutral

Praxis Precision Correlation

10 Most Positive Correlations
EUSG	0.899
AAWW	0.893
VICR	0.884
CVCY	0.865
CASH	0.861
BPRN	0.859
PXLW	0.848
SMSI	0.842
IMAB	0.839
CIZN	0.837

10 Most Negative Correlations
MOSY	-0.87
APOP	-0.826

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Praxis Precision Correlation - Currency/Commodity

0.44
( neutral )

0.42
( neutral )

0.00
( neutral )

0.47
( neutral )

-0.40
( neutral )

-0.51
( weak negative )

Praxis Precision Financials

Annual	2023
Revenue:	$2.45M
Gross Profit:	$2.02M (82.35 %)
EPS:	$-18.69

Q4	2023
Revenue:	$515 000
Gross Profit:	$404 000 (78.45 %)
EPS:	$-2.97

Q3	2023
Revenue:	$468 000
Gross Profit:	$147 000 (31.41 %)
EPS:	$-2.72

Q2	2023
Revenue:	$781 000
Gross Profit:	$469 000 (60.05 %)
EPS:	$-7.38

Financial Reports:

No articles found.

Praxis Precision

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.